Earlier this year, Teva Pharmaceuticals made the controversial decision to discontinue Armodafinil Teva in the United States. This decision has left thousands of patients without an affordable and effective treatment option for conditions such as narcolepsy, sleep apnea, and shift work disorder. To these patients, Armodafinil Teva wasn't just a medication — it was a lifeline.

For many, Armodafinil Teva is not only about staying awake. It's about maintaining productivity, concentration, and the ability to lead normal, fulfilling lives. Many patients have reported significant improvements in their symptoms and overall quality of life while on Armodafinil Teva. Its discontinuation has caused considerable hardship, leading patients to face higher costs with unsubsidized alternatives or ineffective treatments.

The impact of this shortage is profound. According to recent studies, approximately 50,000 people in the U.S. are affected by narcolepsy alone, with many more suffering from related disorders. While alternatives exist, few match the cost-effectiveness and efficacy of Armodafinil Teva, which had provided a vital solution for those without access to more expensive branded medications.

Teva Pharmaceuticals has a responsibility to address this significant healthcare gap. We call on them to bring back Armodafinil Teva to the U.S. market. Furthermore, we urge U.S. regulators to expedite any necessary approvals and support measures that reinstate access to this crucial medication.

The reintroduction of Armodafinil Teva could restore numerous patients' ability to function daily, mean they can resume their roles at work, and improve their quality of life. We hope to unite patients, health professionals, and concerned citizens in this urgent appeal.

We need your support to reach Teva Pharmaceuticals and U.S. regulators with our demand. Sign this petition to reintroduce Armodafinil Teva to the U.S. market and help us secure the access to care that so many patients desperately need. Together, we can make a difference.